Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) Other Non Operating Income (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Other Non Operating Income for 8 consecutive years, with $6.8 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 41.3% to $6.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Dec 2025, down 85.25% year-over-year, with the annual reading at $5.5 million for FY2025, 83.38% down from the prior year.
  • Other Non Operating Income for Q4 2025 was $6.8 million at Precision Biosciences, up from -$1.1 million in the prior quarter.
  • The five-year high for Other Non Operating Income was $12.8 million in Q1 2024, with the low at -$7.3 million in Q4 2022.
  • Average Other Non Operating Income over 5 years is $1.8 million, with a median of $174500.0 recorded in 2023.
  • The sharpest move saw Other Non Operating Income tumbled 6270.83% in 2022, then skyrocketed 8861.46% in 2024.
  • Over 5 years, Other Non Operating Income stood at $2.2 million in 2021, then plummeted by 430.38% to -$7.3 million in 2022, then surged by 119.9% to $1.5 million in 2023, then skyrocketed by 691.96% to $11.5 million in 2024, then tumbled by 41.3% to $6.8 million in 2025.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at $6.8 million, -$1.1 million, and -$1.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.